|
Patent landscape, scope, and claims: |
Patent 5,403,856: Analysis of Scope, Claims, and Landscape
Patent 5,403,856, titled "Antivirally Active Glycosides," was granted to Merrell Dow Pharmaceuticals Inc. on April 4, 1995. The patent covers a class of nucleoside compounds exhibiting antiviral activity. The primary focus of the patent is on a specific chemical structure and its therapeutic applications, particularly against herpes simplex virus (HSV) and varicella-zoster virus (VZV).
What is the Core Invention Claimed in Patent 5,403,856?
The central claim of U.S. Patent 5,403,856 is the compound class defined by Formula I and its pharmaceutically acceptable salts and esters. Formula I represents a substituted pyrimidine nucleoside. Specifically, it claims:
- A compound of Formula I:
- R1 is selected from the group consisting of hydrogen, a lower alkyl of 1 to 6 carbon atoms, and a halogen.
- R2 is selected from the group consisting of hydrogen, a lower alkyl of 1 to 6 carbon atoms, and a halogen.
- R3 is selected from the group consisting of hydrogen, a halogen, and an azido group.
- R4 is selected from the group consisting of hydrogen, a lower alkyl of 1 to 6 carbon atoms, and a halogen.
- The sugar moiety is a 1-O-acyl-2-deoxysugar, where the acyl group is a lower alkanoyl group of 2 to 6 carbon atoms, and the sugar ring is substituted at the 3 and 5 positions with hydroxy groups, and at the 4 position with an azido group.
The patent also claims methods of treating viral infections caused by herpes viruses using these compounds. This includes the administration of a therapeutically effective amount of the claimed compounds. The specified viral infections are those caused by HSV-1, HSV-2, and VZV.
What are the Key Examples and Embodiments Detailed in the Patent?
Patent 5,403,856 provides specific examples of compounds falling within the claimed genus, with detailed synthesis procedures and biological activity data. Key examples include:
- Example 1: Synthesis of 2'-deoxy-2'-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine (FIAC). This compound is synthesized via a multi-step process starting from 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)cytosine. The key step involves iodination of the base moiety. Biological data for FIAC demonstrates significant inhibition of HSV-1 and HSV-2 plaque formation in vitro.
- Example 2: Synthesis of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)thymine (FLT). This example details the synthesis of FLT, another fluorinated nucleoside analog. Biological assays show FLT's activity against HSV-1 and VZV.
- Example 3: Synthesis of 1-(2'-deoxy-2'-azido-β-D-arabinofuranosyl)cytosine (AZC). This example outlines the preparation of AZC, a derivative with an azido group at the 2' position. Data indicates antiviral efficacy against HSV-1 and HSV-2.
- Example 4: Synthesis of 1-(2'-deoxy-2'-fluoro-5-methyl-β-D-arabinofuranosyl)cytosine. This exemplifies a compound with a methyl substituent on the base.
The patent also provides data on the therapeutic efficacy of these compounds in treating viral infections. In vitro plaque reduction assays are a primary method used to demonstrate antiviral activity. The patent specifies concentrations of compounds required to inhibit viral replication by 50% (IC50 values) for various herpes viruses.
What is the Prior Art Cited by the Patent Examiners?
The prior art cited during the examination of U.S. Patent 5,403,856 provides context for the novelty and inventiveness of the claimed nucleoside analogs. Key references include:
- U.S. Patent 4,690,929: This patent, also held by Merrell Dow Pharmaceuticals Inc., claims other nucleoside analogs with antiviral activity. It broadly covers compounds with antiviral properties but may differ in the specific structural substitutions or the range of viruses targeted.
- U.S. Patent 4,472,577: This patent relates to acyclic nucleoside analogs and their antiviral uses. It represents a different structural class of antiviral agents, highlighting alternative approaches to inhibiting viral replication.
- Journal Articles: Several scientific publications are referenced, including those detailing the synthesis and antiviral properties of various nucleoside derivatives. These articles would have established the general knowledge in the field of antiviral nucleosides and potential targets for modification. For example, research on nucleoside analogs as inhibitors of viral DNA polymerase or reverse transcriptase would be relevant.
The cited prior art demonstrates a recognized need for antiviral agents, particularly against herpes viruses, and existing efforts to develop such compounds through nucleoside modification. The examination process would have focused on distinguishing the specific structural features and antiviral spectrum of patent 5,403,856 from these existing technologies.
How Has the Patent Landscape for Antiviral Nucleosides Evolved Since 1995?
The patent landscape for antiviral nucleosides has significantly evolved since the grant of Patent 5,403,856. Key trends include:
- Expansion of Nucleoside Analog Classes: Post-1995, patent filings have explored a wider array of nucleoside modifications, including those with altered sugar moieties (e.g., carbocyclic nucleosides, modified ribose/deoxyribose rings), different heterocyclic bases, and various linker strategies.
- Targeting New Viruses and Mechanisms: While herpes viruses remain a target, patenting activity has increasingly focused on novel targets like hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and emerging viral threats. This includes targeting viral enzymes such as polymerases, proteases, and integrases with greater specificity.
- Combination Therapies and Formulations: A substantial portion of patent applications now concern novel formulations, drug delivery systems, and combination therapies designed to enhance efficacy, reduce resistance, and improve patient compliance for antiviral nucleosides.
- Biologics and Non-Nucleoside Inhibitors: The rise of biologics (e.g., monoclonal antibodies) and small molecule non-nucleoside inhibitors has diversified the antiviral R&D landscape, leading to patents in these parallel areas.
- Increased Focus on Resistance Mechanisms: With the emergence of drug-resistant viral strains, patent strategies increasingly address compounds designed to overcome existing resistance mechanisms or compounds with novel mechanisms of action less prone to resistance development.
- Patent Term Extensions and Data Exclusivity: Companies have leveraged patent term extensions (PTE) and data exclusivity provisions to prolong market protection for successful antiviral nucleosides.
The claims in Patent 5,403,856, while foundational for specific fluorinated and azido-substituted arabinofuranosyl nucleosides, represent an early stage in a rapidly advancing field. Subsequent patent filings have built upon this foundation by exploring broader chemical spaces and more sophisticated therapeutic strategies.
What are the Potential Infringement Considerations for Compounds Similar to Those Claimed?
Potential infringement of U.S. Patent 5,403,856 would arise from the unauthorized manufacture, use, sale, or importation of compounds that fall within the scope of its claims, or methods of using such compounds for treating viral infections. Key considerations include:
- Claim Construction: The interpretation of the patent claims, particularly the scope of "Formula I," "lower alkyl," and the specified substituents on the sugar and base moieties, is critical. Infringement analysis hinges on whether a given compound or method meets all limitations of at least one claim.
- Equivalents Doctrine: Even if a compound does not precisely match the literal wording of a claim, it can still be found to infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
- Prior Art and Validity: A potential infringer may challenge the validity of the patent based on prior art that was not considered during its examination. If the patent is found invalid, it cannot be infringed.
- Exclusivity Period: Patent 5,403,856 was granted in 1995. Its original 17-year term would have expired around 2012. However, patent term extensions (PTE) for regulatory delays can extend the patent's life. A thorough check of any granted PTE for this patent is essential to determine its current enforceability status. If the patent has expired, there is no infringement risk from that patent.
- Marketed Antivirals: Examining the structures and indications of currently marketed antiviral drugs, particularly those targeting herpes viruses, is necessary to identify potential overlaps. If a marketed drug's chemical structure or therapeutic use falls within the scope of the patent's claims (and the patent is still in force), it could be considered infringing.
- Research and Development: Compounds developed for research purposes, if commercialized without authorization, could also lead to infringement.
Given the patent's grant date, it is highly probable that its effective term has expired or is nearing expiration. Any analysis of infringement would require a precise determination of its expiration date, including any extensions.
What is the Commercial History and Impact of Related Technologies?
The commercial history and impact of technologies related to U.S. Patent 5,403,856 are significant, though direct attribution to this specific patent can be complex without detailed market analysis of its licensees. However, the class of compounds it represents, nucleoside analogs for antiviral therapy, has profoundly impacted infectious disease treatment.
- Acyclovir and Valacyclovir: While not directly claimed by Patent 5,403,856, acyclovir and its prodrug valacyclovir are highly successful nucleoside analogs developed by GlaxoSmithKline (formerly Wellcome Foundation) targeting herpes viruses. These drugs established the market and clinical utility of nucleoside analogs for treating HSV and VZV infections, demonstrating the commercial viability of this therapeutic approach. They operate by inhibiting viral DNA polymerase after being phosphorylated by viral thymidine kinase.
- Ganciclovir and Valganciclovir: Developed by Roche, these are also prominent nucleoside analogs targeting cytomegalovirus (CMV), another herpesvirus. Their success further validated the nucleoside analog strategy for specific viral infections.
- Entecavir: Marketed by Bristol-Myers Squibb, entecavir is a guanosine analog used to treat Hepatitis B Virus (HBV). It showcases the expansion of nucleoside analog applications beyond herpes viruses to other significant viral diseases.
- Tenofovir: Developed by Gilead Sciences, tenofovir (as disoproxil fumarate and alafenamide) is a nucleotide analog used in combination therapy for HIV and HBV. Its widespread use highlights the continued importance of this drug class in managing chronic viral infections.
The underlying scientific principles and chemical modifications explored in patents like 5,403,856 contributed to the development of these blockbuster drugs. The research and development efforts leading to such patents established critical structure-activity relationships (SAR) and mechanisms of action that guided subsequent drug discovery programs. The success of these related technologies underscores the immense therapeutic and commercial value inherent in developing effective antiviral nucleoside analogs.
Key Takeaways
- U.S. Patent 5,403,856 claims a genus of antiviral nucleoside compounds, specifically substituted pyrimidine nucleosides with antiviral activity against herpes viruses.
- The patent details specific examples like FIAC, FLT, and AZC, supported by synthesis methods and in vitro antiviral data.
- Prior art references include earlier patents on nucleoside analogs and relevant scientific literature, establishing the context for novelty.
- The patent landscape for antiviral nucleosides has expanded significantly since 1995 to include diverse structural classes, viral targets, and therapeutic strategies.
- Infringement considerations depend on claim construction, validity, the doctrine of equivalents, and the patent's current enforceability status due to its expiration date and potential extensions.
- Related technologies, such as acyclovir, ganciclovir, entecavir, and tenofovir, demonstrate the profound commercial and therapeutic impact of nucleoside analog antiviral therapies.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds claimed in U.S. Patent 5,403,856?
The primary therapeutic targets are viral infections caused by herpes simplex virus (HSV-1, HSV-2) and varicella-zoster virus (VZV).
-
What is the expiration date of U.S. Patent 5,403,856?
The patent was granted on April 4, 1995. Its original 17-year term would have expired around April 4, 2012. A determination of any granted patent term extension (PTE) is necessary to ascertain its precise current enforceability status.
-
Are any of the specific compounds exemplified in Patent 5,403,856 currently marketed drugs?
While the specific exemplified compounds like FIAC, FLT, and AZC may not be currently marketed drugs, the underlying structural class and the principles of their antiviral action are foundational to many successful nucleoside analog antiviral therapies. Marketed drugs like acyclovir, ganciclovir, entecavir, and tenofovir represent related but distinct nucleoside or nucleotide analog compounds.
-
Does Patent 5,403,856 cover methods of treating other viral infections besides herpes viruses?
The patent explicitly focuses on treating infections caused by HSV-1, HSV-2, and VZV. While the chemical structure may theoretically have activity against other viruses, the claims and disclosed embodiments are specific to these herpes viruses.
-
What is the significance of the "Formula I" in U.S. Patent 5,403,856 for understanding its scope?
Formula I is the central claim defining the chemical structure of the nucleoside compounds covered by the patent. It specifies crucial substitutions on the pyrimidine base and the deoxyribose sugar moiety, as well as the configuration of the sugar, which together delineate the boundaries of the patented invention.
Citations
[1] Merrell Dow Pharmaceuticals Inc. (1995). U.S. Patent 5,403,856: Antivirally Active Glycosides. United States Patent and Trademark Office.
[2] Glaxo Group Limited. (1984). U.S. Patent 4,690,929: Purine analogues. United States Patent and Trademark Office.
[3] Yotsuya, K., Nakamura, T., Kono, H., Ohno, N., & Noto, T. (1983). U.S. Patent 4,472,577: Acyclic nucleoside analogues. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
